In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

A use of a diarylamide compound having the structure as shown in formula (I) or a pharmaceutically acceptable salt thereof in preparing a drug which acts as a urea transporter protein inhibitor, and a novel diarylamide compound. The diarylamide compound has urea transporter protein inhibitor effect, and can produce urea selective diuresis in the body without obvious toxicity.

##STR00001##

The present invention relates to the treatment of cardiovascular disease, more particularly to the treatment of subjects suffering from or at risk of suffering from atherosclerotic cardiovascular disease that are hypo-responsive to HIS treatment. The present inventors have found that HIS hypo-responders show remarkable improvements in their blood lipid profiles when their statin therapy is combined with treatment with the CETP inhibitor obicetrapib. In a general aspect, the present invention thus provides methods of treating subjects that are hypo-responsive to high intensity statin (HIS) therapy, said method comprising the administration of a composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate or solvate thereof.

The present invention relates to the treatment of cardiovascular disease, more particularly to the treatment of subjects suffering from or at risk of suffering from atherosclerotic cardiovascular disease that are hypo-responsive to HIS treatment. The present inventors have found that HIS hypo-responders show remarkable improvements in their blood lipid profiles when their statin therapy is combined with treatment with the CETP inhibitor obicetrapib. In a general aspect, the present invention thus provides methods of treating subjects that are hypo-responsive to high intensity statin (HIS) therapy, said method comprising the administration of a composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate or solvate thereof.

The present invention relates to the treatment of cardiovascular disease, more particularly to the treatment of subjects suffering from or at risk of suffering from atherosclerotic cardiovascular disease that are hypo-responsive to HIS treatment. The present inventors have found that HIS hypo-responders show remarkable improvements in their blood lipid profiles when their statin therapy is combined with treatment with the CETP inhibitor obicetrapib. In a general aspect, the present invention thus provides methods of treating subjects that are hypo-responsive to high intensity statin (HIS) therapy, said method comprising the administration of a composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate or solvate thereof.